Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc (ORMP) Covered Calls
As of September 29, 2026, ORMP has 2 covered call opportunities in the coming three months. Return ranges from 8.4 to 12.6% until expiration. Annualized return ranges from 32.0 to 58.0%. The nearest expiration is November 20, 2026. Maximum potential profit is $60.
Read more
Running ORMP covered calls helps you generate consistent income from Oramed Pharmaceuticals Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Oramed Pharmaceuticals Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best ORMP covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if ORMP stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling ORMP covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Oramed Pharmaceuticals Inc covered call is worth writing.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule.
The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Income-focused investors, long-term ORMP holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling ORMP covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Oramed Pharmaceuticals Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile37.30% Neutral
- Market cap (M$)195
- 52 weeks high-14.26%
- 52 weeks low124.40%
- Analyst recommendationHold
3.00 - Target price$7.00
49.58% above the current stock price - Dividend—
- Payout ratio0.00%
- Earnings date2026-11-12
- P/E1.14
- Future P/E—
- EPS (ttm)4.11
- EPS growth next 5 years—
As of September 29, 2026
| 2026-11-20 | 53 | 5.00 | 5.26 | 0.15 | 0.40 | 40.00 | 8.42 | 57.99 | -3.16 | +0.45 | 351 | 0.25 |
| 2027-02-19 | 144 | 5.00 | 5.26 | 0.35 | 0.75 | 60.00 | 12.63 | 32.02 | -7.37 | +0.52 | 192 | 0.40 |
As of September 29, 2026
Sell covered calls with the data behind you
Find the best ORMP covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→